These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 28836555

  • 21. MiR-146a Regulates Inflammatory Infiltration by Macrophages in Polymyositis/Dermatomyositis by Targeting TRAF6 and Affecting IL-17/ICAM-1 Pathway.
    Yin Y, Li F, Shi J, Li S, Cai J, Jiang Y.
    Cell Physiol Biochem; 2016; 40(3-4):486-498. PubMed ID: 27889748
    [Abstract] [Full Text] [Related]

  • 22. Increased IL-21/IL-21R expression and its proinflammatory effects in autoimmune thyroid disease.
    Guan LJ, Wang X, Meng S, Shi LF, Jiang WJ, Xiao L, Shi XH, Xu J, Zhang JA.
    Cytokine; 2015 Apr; 72(2):160-5. PubMed ID: 25647271
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Dysfunction of endothelial progenitor cells is associated with the type I IFN pathway in patients with polymyositis and dermatomyositis.
    Ekholm L, Kahlenberg JM, Barbasso Helmers S, Tjärnlund A, Yalavarthi S, Zhao W, Seto N, Betteridge Z, Lundberg IE, Kaplan MJ.
    Rheumatology (Oxford); 2016 Nov; 55(11):1987-1992. PubMed ID: 27498356
    [Abstract] [Full Text] [Related]

  • 25. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies.
    Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L.
    Arthritis Rheum; 1997 May; 40(5):865-74. PubMed ID: 9153548
    [Abstract] [Full Text] [Related]

  • 26. A Study Based on the Correlation Between Slit2/Robo1 Signaling Pathway Proteins and Polymyositis/Dermatomyositis.
    Chai KX, Chen YQ, Kong LS, Fan PL, Yuan X, Yang J.
    Curr Mol Med; 2020 May; 20(9):717-722. PubMed ID: 32213157
    [Abstract] [Full Text] [Related]

  • 27. [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].
    Chen F, Shu XM, Wang DX, Xie Y, Wang GC.
    Zhonghua Yi Xue Za Zhi; 2012 Aug 21; 92(31):2182-5. PubMed ID: 23158422
    [Abstract] [Full Text] [Related]

  • 28. Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity.
    Suzuki F, Kubota T, Miyazaki Y, Ishikawa K, Ebisawa M, Hirohata S, Ogura T, Mizusawa H, Imai T, Miyasaka N, Nanki T.
    Arthritis Res Ther; 2012 Mar 06; 14(2):R48. PubMed ID: 22394569
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Measurement of platelet-derived microparticle levels using an enzyme-linked immunosorbent assay in polymyositis and dermatomyositis patients.
    Shirafuji T, Hamaguchi H, Higuchi M, Kanda F.
    Muscle Nerve; 2009 May 06; 39(5):586-90. PubMed ID: 19347930
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis.
    Kim GT, Cho ML, Park YE, Yoo WH, Kim JH, Oh HJ, Kim DS, Baek SH, Lee SH, Lee JH, Kim HY, Kim SI.
    Clin Rheumatol; 2010 Mar 06; 29(3):273-9. PubMed ID: 19953283
    [Abstract] [Full Text] [Related]

  • 34. [The levels and clinical significance of serum B cell activating factor in Chinese patients with polymyositis or dermatomyositis].
    Peng QL, Xie Y, Zhang RF, Shu XM, Wang GC.
    Zhonghua Nei Ke Za Zhi; 2012 Mar 06; 51(3):210-3. PubMed ID: 22781895
    [Abstract] [Full Text] [Related]

  • 35. Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis.
    Feng M, Guo H, Zhang C, Wang Y, Liang Z, Zhao X, Qin Y, Wu Y, Liu G, Gao C, Luo J.
    Int Immunopharmacol; 2019 Dec 06; 77():105912. PubMed ID: 31669890
    [Abstract] [Full Text] [Related]

  • 36. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis.
    Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, Johnson MA, Wekerle H, Tschopp J, Jenne D, Hohlfeld R.
    J Clin Invest; 1996 Jun 15; 97(12):2905-10. PubMed ID: 8675705
    [Abstract] [Full Text] [Related]

  • 37. Serum KL-6 in adult patients with polymyositis and dermatomyositis.
    Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N, Soma Y, Tamaki K.
    Rheumatology (Oxford); 2000 Jun 15; 39(6):632-6. PubMed ID: 10888708
    [Abstract] [Full Text] [Related]

  • 38. B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis.
    Peng QL, Shu XM, Wang DX, Wang Y, Lu X, Wang GC.
    Biomark Med; 2014 Jun 15; 8(3):395-403. PubMed ID: 24712431
    [Abstract] [Full Text] [Related]

  • 39. T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients.
    Houtman M, Ekholm L, Hesselberg E, Chemin K, Malmström V, Reed AM, Lundberg IE, Padyukov L.
    Arthritis Res Ther; 2018 Aug 29; 20(1):188. PubMed ID: 30157932
    [Abstract] [Full Text] [Related]

  • 40. Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents.
    Loell I, Raouf J, Chen YW, Shi R, Nennesmo I, Alexanderson H, Dastmalchi M, Nagaraju K, Korotkova M, Lundberg IE.
    Arthritis Res Ther; 2016 Jun 10; 18(1):136. PubMed ID: 27287443
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.